| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Muscular Atrophy | 28 | 2022 | 83 | 6.170 |
Why?
|
| Muscle, Skeletal | 43 | 2026 | 1004 | 4.880 |
Why?
|
| Renal Insufficiency, Chronic | 38 | 2023 | 848 | 4.780 |
Why?
|
| Muscle Proteins | 22 | 2022 | 404 | 3.040 |
Why?
|
| Ubiquitin | 20 | 2015 | 133 | 2.930 |
Why?
|
| Proteasome Endopeptidase Complex | 20 | 2017 | 242 | 2.760 |
Why?
|
| Kidney Diseases | 13 | 2013 | 482 | 2.370 |
Why?
|
| Cachexia | 11 | 2022 | 55 | 2.320 |
Why?
|
| Kidney Failure, Chronic | 24 | 2018 | 941 | 2.070 |
Why?
|
| Myostatin | 8 | 2016 | 22 | 1.930 |
Why?
|
| Water Purification | 3 | 2024 | 19 | 1.870 |
Why?
|
| STAT3 Transcription Factor | 4 | 2020 | 233 | 1.830 |
Why?
|
| Diet, Protein-Restricted | 8 | 2016 | 73 | 1.800 |
Why?
|
| Renal Insufficiency | 6 | 2023 | 252 | 1.590 |
Why?
|
| Keto Acids | 6 | 2016 | 50 | 1.580 |
Why?
|
| Renal Dialysis | 22 | 2020 | 952 | 1.420 |
Why?
|
| Kidney | 13 | 2026 | 1309 | 1.390 |
Why?
|
| Signal Transduction | 33 | 2020 | 4683 | 1.250 |
Why?
|
| Caspase 3 | 13 | 2015 | 127 | 1.210 |
Why?
|
| Insulin Resistance | 7 | 2020 | 681 | 1.190 |
Why?
|
| Water Pollutants, Chemical | 4 | 2024 | 37 | 1.120 |
Why?
|
| Proteolysis | 3 | 2020 | 195 | 1.090 |
Why?
|
| Hydrogen Peroxide | 3 | 2024 | 117 | 1.000 |
Why?
|
| Body Composition | 3 | 2020 | 550 | 1.000 |
Why?
|
| Parathyroid Hormone | 2 | 2017 | 77 | 0.990 |
Why?
|
| Wasting Syndrome | 7 | 2016 | 22 | 0.930 |
Why?
|
| Dietary Proteins | 4 | 2013 | 216 | 0.920 |
Why?
|
| Proto-Oncogene Proteins c-akt | 8 | 2020 | 482 | 0.910 |
Why?
|
| Receptors, Immunologic | 4 | 2026 | 126 | 0.910 |
Why?
|
| Disinfection | 2 | 2024 | 26 | 0.900 |
Why?
|
| Protein Biosynthesis | 3 | 2020 | 580 | 0.890 |
Why?
|
| Muscle Fibers, Skeletal | 4 | 2020 | 104 | 0.870 |
Why?
|
| Acidosis | 7 | 2016 | 99 | 0.860 |
Why?
|
| Animals | 68 | 2026 | 34404 | 0.860 |
Why?
|
| Oxidation-Reduction | 2 | 2024 | 442 | 0.810 |
Why?
|
| Mice, Knockout | 23 | 2026 | 3864 | 0.790 |
Why?
|
| Alkanes | 1 | 2022 | 4 | 0.780 |
Why?
|
| Charcoal | 1 | 2022 | 8 | 0.780 |
Why?
|
| Diabetes Mellitus, Experimental | 6 | 2026 | 147 | 0.780 |
Why?
|
| Muscular Diseases | 4 | 2017 | 124 | 0.770 |
Why?
|
| Insulin | 11 | 2026 | 1151 | 0.750 |
Why?
|
| Mice | 42 | 2026 | 18482 | 0.710 |
Why?
|
| Proteins | 8 | 2013 | 1027 | 0.700 |
Why?
|
| Insulin-Like Growth Factor I | 9 | 2014 | 323 | 0.700 |
Why?
|
| Malnutrition | 5 | 2012 | 156 | 0.690 |
Why?
|
| Phosphatidylinositol 3-Kinases | 7 | 2010 | 344 | 0.690 |
Why?
|
| Interleukin-6 | 7 | 2020 | 419 | 0.670 |
Why?
|
| Angiotensin II | 5 | 2020 | 135 | 0.670 |
Why?
|
| Naphthols | 1 | 2020 | 9 | 0.650 |
Why?
|
| Adipose Tissue, White | 2 | 2019 | 95 | 0.640 |
Why?
|
| Histone Demethylases | 1 | 2020 | 36 | 0.640 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2020 | 31 | 0.640 |
Why?
|
| F-Box Proteins | 1 | 2020 | 32 | 0.630 |
Why?
|
| Dioxygenases | 1 | 2020 | 72 | 0.630 |
Why?
|
| Receptor, Insulin | 2 | 2013 | 64 | 0.630 |
Why?
|
| Fibrosis | 12 | 2022 | 416 | 0.630 |
Why?
|
| Weight Gain | 2 | 2020 | 384 | 0.620 |
Why?
|
| Nephrology | 5 | 2021 | 156 | 0.620 |
Why?
|
| Arteriovenous Shunt, Surgical | 5 | 2020 | 92 | 0.600 |
Why?
|
| Drinking Water | 2 | 2024 | 16 | 0.600 |
Why?
|
| Regeneration | 3 | 2010 | 231 | 0.590 |
Why?
|
| Diabetic Nephropathies | 6 | 2026 | 116 | 0.580 |
Why?
|
| Mice, Inbred C57BL | 21 | 2026 | 4768 | 0.570 |
Why?
|
| Sulfonamides | 1 | 2020 | 296 | 0.550 |
Why?
|
| Protein-Energy Malnutrition | 4 | 2013 | 60 | 0.540 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2015 | 254 | 0.540 |
Why?
|
| Insulin Receptor Substrate Proteins | 6 | 2020 | 72 | 0.540 |
Why?
|
| Enzyme Inhibitors | 2 | 2020 | 566 | 0.530 |
Why?
|
| Parathyroid Hormone-Related Protein | 1 | 2017 | 10 | 0.530 |
Why?
|
| CCAAT-Enhancer-Binding Protein-delta | 2 | 2015 | 6 | 0.530 |
Why?
|
| Humans | 92 | 2026 | 131759 | 0.520 |
Why?
|
| Peptide Hydrolases | 4 | 2010 | 131 | 0.510 |
Why?
|
| Kidney Transplantation | 2 | 2020 | 572 | 0.510 |
Why?
|
| Adipose Tissue, Brown | 1 | 2017 | 86 | 0.500 |
Why?
|
| Chronic Kidney Disease-Mineral and Bone Disorder | 1 | 2016 | 13 | 0.500 |
Why?
|
| Phosphorylation | 8 | 2020 | 1571 | 0.490 |
Why?
|
| Caspases | 7 | 2010 | 157 | 0.490 |
Why?
|
| Disinfectants | 3 | 2024 | 29 | 0.490 |
Why?
|
| Neointima | 5 | 2020 | 46 | 0.480 |
Why?
|
| Cell Line | 9 | 2020 | 2606 | 0.480 |
Why?
|
| Muscles | 3 | 2023 | 222 | 0.460 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2015 | 6 | 0.460 |
Why?
|
| Chronic Disease | 9 | 2016 | 1235 | 0.450 |
Why?
|
| Uremia | 2 | 2005 | 37 | 0.440 |
Why?
|
| Disease Models, Animal | 16 | 2020 | 4685 | 0.440 |
Why?
|
| Glucocorticoids | 5 | 2009 | 350 | 0.440 |
Why?
|
| Muscle, Smooth, Vascular | 4 | 2020 | 232 | 0.430 |
Why?
|
| Biochemistry | 1 | 2013 | 9 | 0.410 |
Why?
|
| Glomerular Filtration Rate | 4 | 2023 | 567 | 0.410 |
Why?
|
| Renal Replacement Therapy | 2 | 2014 | 159 | 0.410 |
Why?
|
| Rats | 14 | 2020 | 3460 | 0.410 |
Why?
|
| Endothelial Cells | 5 | 2020 | 536 | 0.400 |
Why?
|
| MicroRNAs | 3 | 2021 | 895 | 0.390 |
Why?
|
| Nutrition Disorders | 3 | 2003 | 27 | 0.390 |
Why?
|
| Satellite Cells, Skeletal Muscle | 2 | 2010 | 37 | 0.390 |
Why?
|
| Acetonitriles | 1 | 2012 | 3 | 0.390 |
Why?
|
| Halogenation | 1 | 2012 | 5 | 0.380 |
Why?
|
| Myoblasts, Skeletal | 2 | 2014 | 9 | 0.380 |
Why?
|
| SKP Cullin F-Box Protein Ligases | 5 | 2020 | 17 | 0.380 |
Why?
|
| Diet, Reducing | 1 | 2013 | 90 | 0.380 |
Why?
|
| Myocytes, Smooth Muscle | 3 | 2020 | 185 | 0.380 |
Why?
|
| Male | 58 | 2026 | 65274 | 0.370 |
Why?
|
| Acetamides | 1 | 2012 | 44 | 0.370 |
Why?
|
| Ubiquitin-Protein Ligases | 8 | 2020 | 364 | 0.370 |
Why?
|
| Cells, Cultured | 13 | 2020 | 2969 | 0.370 |
Why?
|
| Colonic Neoplasms | 1 | 2015 | 265 | 0.360 |
Why?
|
| Ultraviolet Rays | 2 | 2024 | 195 | 0.360 |
Why?
|
| Chlorine | 2 | 2022 | 15 | 0.360 |
Why?
|
| Myofibroblasts | 4 | 2020 | 62 | 0.360 |
Why?
|
| Multienzyme Complexes | 4 | 2004 | 77 | 0.350 |
Why?
|
| Amino Acids | 6 | 2016 | 620 | 0.350 |
Why?
|
| Cysteine Endopeptidases | 4 | 2004 | 113 | 0.350 |
Why?
|
| Fibroblasts | 6 | 2020 | 864 | 0.340 |
Why?
|
| Muscle Development | 1 | 2011 | 71 | 0.340 |
Why?
|
| Homeostasis | 2 | 2017 | 714 | 0.340 |
Why?
|
| Muscle Cells | 2 | 2010 | 25 | 0.330 |
Why?
|
| Tripartite Motif Proteins | 4 | 2020 | 24 | 0.330 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2011 | 112 | 0.320 |
Why?
|
| Acid-Base Equilibrium | 3 | 2009 | 60 | 0.320 |
Why?
|
| Inflammation | 9 | 2022 | 1493 | 0.320 |
Why?
|
| Physical Conditioning, Animal | 2 | 2017 | 86 | 0.320 |
Why?
|
| Macrophages | 4 | 2020 | 665 | 0.320 |
Why?
|
| Chemokine CXCL6 | 1 | 2009 | 8 | 0.320 |
Why?
|
| Actins | 8 | 2017 | 317 | 0.310 |
Why?
|
| Energy Metabolism | 6 | 2019 | 785 | 0.310 |
Why?
|
| Neutrophil Infiltration | 1 | 2009 | 65 | 0.300 |
Why?
|
| Stem Cells | 2 | 2016 | 713 | 0.300 |
Why?
|
| Gene Expression | 5 | 2020 | 1502 | 0.300 |
Why?
|
| Serum Amyloid A Protein | 1 | 2009 | 22 | 0.300 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2013 | 1413 | 0.300 |
Why?
|
| Living Donors | 2 | 2020 | 116 | 0.290 |
Why?
|
| NF-kappa B | 3 | 2020 | 449 | 0.290 |
Why?
|
| Body Weight | 4 | 2020 | 990 | 0.290 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2022 | 93 | 0.290 |
Why?
|
| Obesity | 2 | 2026 | 2390 | 0.290 |
Why?
|
| Creatinine | 4 | 2023 | 402 | 0.280 |
Why?
|
| Dietary Fats | 1 | 2010 | 276 | 0.280 |
Why?
|
| Exercise Therapy | 1 | 2009 | 175 | 0.260 |
Why?
|
| Nephrectomy | 3 | 2020 | 175 | 0.250 |
Why?
|
| STAT6 Transcription Factor | 2 | 2017 | 32 | 0.250 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2006 | 21 | 0.240 |
Why?
|
| RNA, Messenger | 8 | 2020 | 2569 | 0.230 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2006 | 58 | 0.230 |
Why?
|
| Middle Aged | 25 | 2020 | 28892 | 0.230 |
Why?
|
| Anorexia | 1 | 2005 | 23 | 0.230 |
Why?
|
| Societies, Medical | 3 | 2005 | 796 | 0.230 |
Why?
|
| Soil | 1 | 2026 | 77 | 0.230 |
Why?
|
| Diabetes Insipidus | 1 | 2004 | 16 | 0.220 |
Why?
|
| Thirst | 1 | 2004 | 5 | 0.220 |
Why?
|
| Metabolic Diseases | 1 | 2006 | 137 | 0.220 |
Why?
|
| Cytokines | 5 | 2020 | 1348 | 0.220 |
Why?
|
| Receptors, Notch | 2 | 2019 | 204 | 0.220 |
Why?
|
| rho-Associated Kinases | 2 | 2015 | 48 | 0.220 |
Why?
|
| Photolysis | 1 | 2024 | 10 | 0.220 |
Why?
|
| Cross-Sectional Studies | 6 | 2018 | 3836 | 0.220 |
Why?
|
| Diet, High-Fat | 3 | 2026 | 264 | 0.220 |
Why?
|
| Dietary Supplements | 4 | 2016 | 454 | 0.210 |
Why?
|
| Hypernatremia | 1 | 2004 | 32 | 0.210 |
Why?
|
| Goals | 1 | 2005 | 125 | 0.210 |
Why?
|
| Adult | 20 | 2020 | 31700 | 0.210 |
Why?
|
| Hypothalamus | 1 | 2005 | 205 | 0.200 |
Why?
|
| Enzyme Activation | 4 | 2006 | 590 | 0.200 |
Why?
|
| Female | 31 | 2020 | 71214 | 0.200 |
Why?
|
| RNA Interference | 3 | 2015 | 496 | 0.200 |
Why?
|
| Nutritional Status | 5 | 2013 | 303 | 0.200 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2017 | 173 | 0.200 |
Why?
|
| Myofibrils | 3 | 2010 | 24 | 0.200 |
Why?
|
| Metabolism | 2 | 2013 | 45 | 0.200 |
Why?
|
| Halogens | 1 | 2022 | 4 | 0.200 |
Why?
|
| Alkenes | 1 | 2022 | 8 | 0.190 |
Why?
|
| Adipose Tissue | 2 | 2016 | 495 | 0.190 |
Why?
|
| Serum Albumin | 6 | 2008 | 110 | 0.190 |
Why?
|
| Electrodes | 1 | 2022 | 81 | 0.190 |
Why?
|
| Endopeptidases | 1 | 2003 | 108 | 0.190 |
Why?
|
| Cell Communication | 2 | 2020 | 196 | 0.190 |
Why?
|
| Neoplasms | 3 | 2016 | 2966 | 0.190 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2020 | 643 | 0.190 |
Why?
|
| Body Mass Index | 3 | 2020 | 1695 | 0.190 |
Why?
|
| Adenosine Triphosphate | 6 | 2017 | 265 | 0.180 |
Why?
|
| Ureteral Obstruction | 4 | 2017 | 104 | 0.170 |
Why?
|
| Dimethylnitrosamine | 1 | 2020 | 3 | 0.170 |
Why?
|
| Osmosis | 1 | 2020 | 17 | 0.170 |
Why?
|
| Re-Epithelialization | 1 | 2020 | 12 | 0.170 |
Why?
|
| Class Ib Phosphatidylinositol 3-Kinase | 1 | 2020 | 5 | 0.170 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2020 | 29 | 0.170 |
Why?
|
| Jagged-1 Protein | 1 | 2020 | 53 | 0.160 |
Why?
|
| DNA, Ribosomal | 1 | 2020 | 53 | 0.160 |
Why?
|
| Fibronectins | 2 | 2017 | 99 | 0.160 |
Why?
|
| Hypoalbuminemia | 2 | 2011 | 17 | 0.160 |
Why?
|
| Hand Strength | 1 | 2020 | 59 | 0.160 |
Why?
|
| Arteriovenous Fistula | 1 | 2020 | 55 | 0.160 |
Why?
|
| Energy Intake | 1 | 2002 | 501 | 0.160 |
Why?
|
| Consensus | 2 | 2013 | 557 | 0.150 |
Why?
|
| Human Growth Hormone | 2 | 2011 | 75 | 0.150 |
Why?
|
| Sodium Bicarbonate | 1 | 2019 | 55 | 0.150 |
Why?
|
| Cell Differentiation | 3 | 2020 | 1948 | 0.150 |
Why?
|
| Apoptosis | 2 | 2015 | 1861 | 0.150 |
Why?
|
| Chromatography, Liquid | 1 | 2020 | 240 | 0.150 |
Why?
|
| Acute-Phase Reaction | 3 | 2004 | 7 | 0.150 |
Why?
|
| Urea | 2 | 2014 | 226 | 0.150 |
Why?
|
| Tetracycline | 1 | 2018 | 75 | 0.150 |
Why?
|
| Respiratory Mucosa | 1 | 2019 | 96 | 0.140 |
Why?
|
| Transfection | 4 | 2015 | 960 | 0.140 |
Why?
|
| Potassium | 2 | 2019 | 270 | 0.140 |
Why?
|
| Transplant Recipients | 1 | 2020 | 233 | 0.140 |
Why?
|
| Histamine H2 Antagonists | 1 | 2018 | 49 | 0.140 |
Why?
|
| S100 Proteins | 2 | 2015 | 40 | 0.140 |
Why?
|
| Fellowships and Scholarships | 1 | 2021 | 324 | 0.140 |
Why?
|
| Up-Regulation | 3 | 2014 | 832 | 0.140 |
Why?
|
| Interferon-gamma | 1 | 2020 | 542 | 0.140 |
Why?
|
| Patient Care | 1 | 1998 | 99 | 0.140 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 288 | 0.140 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2011 | 694 | 0.130 |
Why?
|
| Hip Fractures | 1 | 2018 | 68 | 0.130 |
Why?
|
| Cell Proliferation | 3 | 2020 | 2483 | 0.130 |
Why?
|
| Cystatin C | 1 | 2018 | 71 | 0.130 |
Why?
|
| Aged | 18 | 2020 | 21259 | 0.130 |
Why?
|
| Uncoupling Protein 1 | 1 | 2017 | 32 | 0.130 |
Why?
|
| Ubiquitins | 1 | 2017 | 39 | 0.130 |
Why?
|
| Cardiomyopathies | 1 | 2022 | 516 | 0.130 |
Why?
|
| Nutritional Physiological Phenomena | 3 | 2002 | 85 | 0.130 |
Why?
|
| Kidney Tubules | 2 | 2017 | 77 | 0.130 |
Why?
|
| Histones | 1 | 2020 | 533 | 0.130 |
Why?
|
| Trichloroacetic Acid | 1 | 2016 | 5 | 0.120 |
Why?
|
| Trihalomethanes | 1 | 2016 | 5 | 0.120 |
Why?
|
| Disease Progression | 3 | 2019 | 2221 | 0.120 |
Why?
|
| Reperfusion Injury | 1 | 2017 | 109 | 0.120 |
Why?
|
| Immunohistochemistry | 3 | 2015 | 1610 | 0.120 |
Why?
|
| Biomarkers | 9 | 2019 | 3407 | 0.120 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2016 | 17 | 0.120 |
Why?
|
| Proteinuria | 3 | 2012 | 106 | 0.120 |
Why?
|
| Polymorphism, Genetic | 1 | 2019 | 794 | 0.120 |
Why?
|
| S100 Calcium-Binding Protein A4 | 4 | 2019 | 21 | 0.120 |
Why?
|
| Bone Marrow Cells | 1 | 2017 | 244 | 0.120 |
Why?
|
| Atrial Fibrillation | 1 | 2023 | 734 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 4 | 2014 | 1218 | 0.120 |
Why?
|
| DNA Damage | 1 | 2019 | 527 | 0.120 |
Why?
|
| Potassium Radioisotopes | 1 | 2015 | 7 | 0.120 |
Why?
|
| Cell Movement | 2 | 2020 | 886 | 0.120 |
Why?
|
| Proton Pump Inhibitors | 1 | 2018 | 278 | 0.120 |
Why?
|
| Janus Kinase 3 | 1 | 2015 | 16 | 0.120 |
Why?
|
| Hypertension | 2 | 2020 | 1360 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 1236 | 0.110 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2006 | 1146 | 0.110 |
Why?
|
| Receptors, Cell Surface | 1 | 2017 | 432 | 0.110 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 766 | 0.110 |
Why?
|
| Financing, Organized | 1 | 2014 | 21 | 0.110 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2016 | 217 | 0.110 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2015 | 78 | 0.110 |
Why?
|
| 3' Untranslated Regions | 2 | 2014 | 164 | 0.110 |
Why?
|
| Receptor, Notch1 | 1 | 2015 | 75 | 0.110 |
Why?
|
| Treatment Outcome | 7 | 2019 | 12993 | 0.110 |
Why?
|
| Actomyosin | 2 | 2005 | 5 | 0.110 |
Why?
|
| Renal Elimination | 1 | 2014 | 11 | 0.110 |
Why?
|
| Ammonia | 1 | 2014 | 70 | 0.110 |
Why?
|
| RNA, Small Interfering | 2 | 2013 | 665 | 0.110 |
Why?
|
| Uncertainty | 1 | 2014 | 96 | 0.110 |
Why?
|
| Inflammation Mediators | 2 | 2013 | 228 | 0.100 |
Why?
|
| Bone and Bones | 1 | 2016 | 300 | 0.100 |
Why?
|
| Trans-Activators | 1 | 2017 | 692 | 0.100 |
Why?
|
| Pyrroles | 1 | 2015 | 186 | 0.100 |
Why?
|
| Bicarbonates | 3 | 2019 | 98 | 0.100 |
Why?
|
| Amino Acids, Essential | 1 | 2013 | 22 | 0.100 |
Why?
|
| Prospective Studies | 4 | 2020 | 6507 | 0.100 |
Why?
|
| 3T3-L1 Cells | 2 | 2019 | 53 | 0.100 |
Why?
|
| Piperidines | 1 | 2015 | 231 | 0.100 |
Why?
|
| Sarcopenia | 1 | 2014 | 56 | 0.100 |
Why?
|
| Activins | 1 | 2013 | 73 | 0.100 |
Why?
|
| Research Personnel | 1 | 2014 | 139 | 0.100 |
Why?
|
| Patient Compliance | 1 | 2016 | 469 | 0.100 |
Why?
|
| C-Reactive Protein | 4 | 2017 | 455 | 0.100 |
Why?
|
| Transcription, Genetic | 4 | 2006 | 1398 | 0.100 |
Why?
|
| Recombinant Proteins | 3 | 2017 | 1316 | 0.100 |
Why?
|
| I-kappa B Kinase | 1 | 2013 | 57 | 0.100 |
Why?
|
| Acute Kidney Injury | 1 | 2020 | 689 | 0.100 |
Why?
|
| Decarboxylation | 1 | 2012 | 3 | 0.100 |
Why?
|
| Chlorophyta | 1 | 2012 | 4 | 0.100 |
Why?
|
| Chloramines | 1 | 2012 | 5 | 0.100 |
Why?
|
| Asparagine | 1 | 2012 | 22 | 0.100 |
Why?
|
| Exercise | 1 | 2019 | 866 | 0.100 |
Why?
|
| Tyrosine | 1 | 2013 | 148 | 0.100 |
Why?
|
| Glucose Intolerance | 1 | 2013 | 78 | 0.090 |
Why?
|
| History, 21st Century | 1 | 2013 | 263 | 0.090 |
Why?
|
| Immunoglobulin J Recombination Signal Sequence-Binding Protein | 3 | 2019 | 14 | 0.090 |
Why?
|
| Vasoconstrictor Agents | 2 | 2020 | 135 | 0.090 |
Why?
|
| History, 20th Century | 1 | 2013 | 366 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2015 | 445 | 0.090 |
Why?
|
| Glutathione Transferase | 1 | 2012 | 145 | 0.090 |
Why?
|
| YY1 Transcription Factor | 1 | 2011 | 17 | 0.090 |
Why?
|
| Interleukin-1beta | 2 | 2023 | 159 | 0.090 |
Why?
|
| Argininosuccinic Aciduria | 1 | 2011 | 52 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 2 | 2015 | 1489 | 0.090 |
Why?
|
| Argininosuccinate Lyase | 1 | 2011 | 62 | 0.090 |
Why?
|
| Peptide Fragments | 2 | 2006 | 781 | 0.090 |
Why?
|
| Mice, Inbred Strains | 2 | 2011 | 297 | 0.090 |
Why?
|
| Time Factors | 4 | 2019 | 6280 | 0.080 |
Why?
|
| Gene Knockdown Techniques | 3 | 2019 | 382 | 0.080 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2011 | 112 | 0.080 |
Why?
|
| Liver Cirrhosis | 1 | 2018 | 901 | 0.080 |
Why?
|
| Cobra Cardiotoxin Proteins | 1 | 2010 | 5 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 618 | 0.080 |
Why?
|
| Myogenic Regulatory Factor 5 | 1 | 2010 | 1 | 0.080 |
Why?
|
| Myogenin | 1 | 2010 | 9 | 0.080 |
Why?
|
| RNA, Ribosomal | 1 | 2010 | 52 | 0.080 |
Why?
|
| Chemokine CXCL16 | 1 | 2009 | 4 | 0.080 |
Why?
|
| MyoD Protein | 1 | 2010 | 22 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 1008 | 0.080 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2010 | 114 | 0.080 |
Why?
|
| Physical Endurance | 1 | 2009 | 42 | 0.080 |
Why?
|
| Chemokines | 1 | 2009 | 127 | 0.070 |
Why?
|
| Receptors, Angiotensin | 1 | 2009 | 20 | 0.070 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2010 | 240 | 0.070 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2009 | 25 | 0.070 |
Why?
|
| Risk Factors | 6 | 2011 | 10961 | 0.070 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2009 | 105 | 0.070 |
Why?
|
| Gene Deletion | 2 | 2010 | 773 | 0.070 |
Why?
|
| Adenoviridae | 1 | 2011 | 582 | 0.070 |
Why?
|
| Cell Culture Techniques | 1 | 2010 | 275 | 0.070 |
Why?
|
| Mice, Transgenic | 4 | 2017 | 2363 | 0.070 |
Why?
|
| Nitric Oxide | 1 | 2011 | 466 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2014 | 557 | 0.070 |
Why?
|
| Cell Division | 1 | 2010 | 731 | 0.070 |
Why?
|
| Myositis | 1 | 2010 | 106 | 0.070 |
Why?
|
| Heart Diseases | 1 | 2013 | 505 | 0.070 |
Why?
|
| Extracellular Matrix Proteins | 3 | 2017 | 158 | 0.070 |
Why?
|
| Anthropometry | 2 | 2009 | 190 | 0.070 |
Why?
|
| Swimming Pools | 2 | 2019 | 12 | 0.070 |
Why?
|
| Nitric Oxide Synthase | 2 | 2011 | 168 | 0.070 |
Why?
|
| Spain | 2 | 2019 | 62 | 0.070 |
Why?
|
| Carotid Artery, Common | 2 | 2020 | 60 | 0.070 |
Why?
|
| Losartan | 2 | 2004 | 35 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2013 | 1835 | 0.070 |
Why?
|
| Ghrelin | 1 | 2007 | 58 | 0.070 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2004 | 57 | 0.070 |
Why?
|
| Myoblasts | 1 | 2007 | 34 | 0.070 |
Why?
|
| Models, Biological | 3 | 2014 | 1395 | 0.070 |
Why?
|
| Fatty Acids | 1 | 2010 | 377 | 0.070 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 3692 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 3 | 2015 | 388 | 0.070 |
Why?
|
| Longitudinal Studies | 4 | 2006 | 1518 | 0.070 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2015 | 742 | 0.060 |
Why?
|
| Albuminuria | 2 | 2004 | 106 | 0.060 |
Why?
|
| Molecular Sequence Data | 2 | 2009 | 3616 | 0.060 |
Why?
|
| Vascular Patency | 2 | 2019 | 181 | 0.060 |
Why?
|
| Protein Modification, Translational | 1 | 2006 | 2 | 0.060 |
Why?
|
| Aluminum Silicates | 1 | 2026 | 3 | 0.060 |
Why?
|
| Aging | 1 | 2014 | 1266 | 0.060 |
Why?
|
| Sp1 Transcription Factor | 2 | 2006 | 37 | 0.060 |
Why?
|
| Proteasome Inhibitors | 1 | 2006 | 57 | 0.060 |
Why?
|
| Plasmids | 2 | 2004 | 455 | 0.060 |
Why?
|
| Nitrogen | 2 | 2004 | 122 | 0.060 |
Why?
|
| Minerals | 1 | 2026 | 59 | 0.060 |
Why?
|
| Thiazolidinediones | 1 | 2006 | 79 | 0.060 |
Why?
|
| Adiponectin | 1 | 2006 | 124 | 0.060 |
Why?
|
| Mice, Mutant Strains | 1 | 2006 | 366 | 0.060 |
Why?
|
| Substrate Specificity | 1 | 2006 | 286 | 0.060 |
Why?
|
| Amino Acid Sequence | 1 | 2009 | 2565 | 0.060 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2017 | 139 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 3916 | 0.060 |
Why?
|
| Eating | 2 | 2007 | 382 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2004 | 137 | 0.050 |
Why?
|
| Cytochromes c | 1 | 2004 | 51 | 0.050 |
Why?
|
| Monocytes | 2 | 2017 | 337 | 0.050 |
Why?
|
| Kinetics | 4 | 2017 | 1104 | 0.050 |
Why?
|
| Affect | 1 | 2004 | 170 | 0.050 |
Why?
|
| Double-Blind Method | 4 | 2011 | 1638 | 0.050 |
Why?
|
| Serine | 1 | 2004 | 163 | 0.050 |
Why?
|
| Bone Marrow Transplantation | 2 | 2017 | 590 | 0.050 |
Why?
|
| Calcium-Binding Proteins | 2 | 2015 | 328 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2005 | 430 | 0.050 |
Why?
|
| Young Adult | 5 | 2019 | 10099 | 0.050 |
Why?
|
| Transcription Factors | 4 | 2017 | 2438 | 0.050 |
Why?
|
| Iron | 1 | 2026 | 310 | 0.050 |
Why?
|
| Albumins | 1 | 2003 | 92 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2015 | 3133 | 0.050 |
Why?
|
| Infusions, Parenteral | 1 | 2002 | 78 | 0.050 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2023 | 129 | 0.050 |
Why?
|
| Protein Conformation | 1 | 2004 | 811 | 0.050 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 1 | 2002 | 22 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2006 | 475 | 0.050 |
Why?
|
| Fibrinogen | 1 | 2003 | 166 | 0.050 |
Why?
|
| Down-Regulation | 2 | 2020 | 659 | 0.050 |
Why?
|
| Protein Deficiency | 1 | 2002 | 19 | 0.050 |
Why?
|
| Diet | 1 | 2009 | 1119 | 0.050 |
Why?
|
| Inflammasomes | 1 | 2023 | 157 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2002 | 89 | 0.040 |
Why?
|
| Nephrologists | 1 | 2021 | 17 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2006 | 1103 | 0.040 |
Why?
|
| Models, Animal | 2 | 2015 | 460 | 0.040 |
Why?
|
| Rats, Inbred F344 | 2 | 2014 | 99 | 0.040 |
Why?
|
| Acute-Phase Proteins | 1 | 2001 | 45 | 0.040 |
Why?
|
| Patient Selection | 2 | 2016 | 726 | 0.040 |
Why?
|
| Heart Atria | 1 | 2023 | 336 | 0.040 |
Why?
|
| Integrin beta3 | 1 | 2020 | 28 | 0.040 |
Why?
|
| United States | 4 | 2013 | 11812 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 5297 | 0.040 |
Why?
|
| Ribonucleases | 3 | 2002 | 41 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2020 | 232 | 0.040 |
Why?
|
| Aged, 80 and over | 5 | 2013 | 6915 | 0.040 |
Why?
|
| Cadherins | 1 | 2020 | 178 | 0.040 |
Why?
|
| Adipocytes, White | 1 | 2019 | 27 | 0.040 |
Why?
|
| Leptin | 1 | 2001 | 219 | 0.040 |
Why?
|
| Lewis Bases | 1 | 2018 | 1 | 0.040 |
Why?
|
| Wounds and Injuries | 1 | 2003 | 395 | 0.040 |
Why?
|
| Cell Dedifferentiation | 1 | 2019 | 21 | 0.040 |
Why?
|
| Adsorption | 1 | 2018 | 34 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2004 | 1912 | 0.040 |
Why?
|
| Silicates | 1 | 2018 | 7 | 0.040 |
Why?
|
| Sunlight | 1 | 2018 | 27 | 0.040 |
Why?
|
| Feces | 1 | 2002 | 725 | 0.040 |
Why?
|
| Tetracyclines | 1 | 2018 | 19 | 0.040 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2019 | 159 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2019 | 107 | 0.040 |
Why?
|
| Atherosclerosis | 1 | 2006 | 947 | 0.040 |
Why?
|
| Catalysis | 1 | 2018 | 137 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 1406 | 0.040 |
Why?
|
| Sepsis | 1 | 2003 | 501 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2015 | 1018 | 0.030 |
Why?
|
| Integrin beta1 | 1 | 2017 | 54 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2019 | 17662 | 0.030 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2017 | 42 | 0.030 |
Why?
|
| Interleukin-4 Receptor alpha Subunit | 1 | 2017 | 13 | 0.030 |
Why?
|
| Cofilin 1 | 1 | 2017 | 12 | 0.030 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2017 | 105 | 0.030 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2017 | 118 | 0.030 |
Why?
|
| Myocytes, Cardiac | 1 | 2022 | 673 | 0.030 |
Why?
|
| Peritoneal Dialysis | 1 | 1998 | 131 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2017 | 301 | 0.030 |
Why?
|
| Cardiovascular Diseases | 2 | 2012 | 2082 | 0.030 |
Why?
|
| Th2 Cells | 1 | 2017 | 186 | 0.030 |
Why?
|
| Quality of Life | 2 | 2021 | 2115 | 0.030 |
Why?
|
| Smad3 Protein | 1 | 2016 | 56 | 0.030 |
Why?
|
| Swimming | 1 | 2016 | 30 | 0.030 |
Why?
|
| Curriculum | 1 | 2021 | 784 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2017 | 231 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2017 | 773 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1626 | 0.030 |
Why?
|
| Receptor Cross-Talk | 1 | 2015 | 36 | 0.030 |
Why?
|
| Cardiac Myosins | 1 | 2015 | 11 | 0.030 |
Why?
|
| Myosin Light Chains | 1 | 2015 | 14 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 1 | 2016 | 382 | 0.030 |
Why?
|
| Umbilical Veins | 1 | 2015 | 64 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 2015 | 145 | 0.030 |
Why?
|
| Interleukin-13 | 1 | 2015 | 96 | 0.030 |
Why?
|
| Folic Acid | 1 | 2017 | 288 | 0.030 |
Why?
|
| Foundations | 1 | 2014 | 23 | 0.030 |
Why?
|
| Jugular Veins | 1 | 2015 | 74 | 0.030 |
Why?
|
| Collagen Type I | 1 | 2015 | 114 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2017 | 1020 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2015 | 134 | 0.030 |
Why?
|
| Kidney Concentrating Ability | 1 | 2014 | 16 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2017 | 810 | 0.030 |
Why?
|
| Class Ia Phosphatidylinositol 3-Kinase | 1 | 2014 | 7 | 0.030 |
Why?
|
| Wnt3A Protein | 1 | 2014 | 11 | 0.030 |
Why?
|
| Water-Electrolyte Balance | 1 | 2014 | 81 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2018 | 3696 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 1347 | 0.030 |
Why?
|
| Renin-Angiotensin System | 2 | 2005 | 105 | 0.030 |
Why?
|
| Metabolomics | 1 | 2017 | 493 | 0.030 |
Why?
|
| Orosomucoid | 2 | 2004 | 9 | 0.030 |
Why?
|
| Ceruloplasmin | 2 | 2004 | 13 | 0.030 |
Why?
|
| Membrane Transport Proteins | 1 | 2014 | 185 | 0.020 |
Why?
|
| Mutation | 3 | 2017 | 6194 | 0.020 |
Why?
|
| Plasma Volume | 2 | 2003 | 12 | 0.020 |
Why?
|
| Obesity, Abdominal | 1 | 2013 | 41 | 0.020 |
Why?
|
| Dexamethasone | 2 | 2006 | 262 | 0.020 |
Why?
|
| Snail Family Transcription Factors | 1 | 2012 | 28 | 0.020 |
Why?
|
| Intercellular Junctions | 1 | 2012 | 25 | 0.020 |
Why?
|
| Aldehydes | 1 | 2012 | 28 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2015 | 371 | 0.020 |
Why?
|
| Adipokines | 1 | 2013 | 121 | 0.020 |
Why?
|
| Nutrition Policy | 1 | 2013 | 91 | 0.020 |
Why?
|
| Lipid Peroxidation | 1 | 2012 | 91 | 0.020 |
Why?
|
| Enterobacter | 1 | 1972 | 13 | 0.020 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 1971 | 20 | 0.020 |
Why?
|
| Cellular Senescence | 1 | 2014 | 218 | 0.020 |
Why?
|
| Argininosuccinate Synthase | 1 | 2011 | 25 | 0.020 |
Why?
|
| Nutrition Assessment | 1 | 2013 | 125 | 0.020 |
Why?
|
| Nitrites | 1 | 2011 | 48 | 0.020 |
Why?
|
| Texas | 1 | 2020 | 3622 | 0.020 |
Why?
|
| Aminoimidazole Carboxamide | 1 | 2011 | 18 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 1790 | 0.020 |
Why?
|
| DNA Transposable Elements | 1 | 2012 | 182 | 0.020 |
Why?
|
| Time-to-Treatment | 1 | 2013 | 215 | 0.020 |
Why?
|
| Mitochondria, Muscle | 1 | 2011 | 37 | 0.020 |
Why?
|
| Ribonucleotides | 1 | 2011 | 31 | 0.020 |
Why?
|
| Protein Phosphatase 2C | 1 | 2011 | 61 | 0.020 |
Why?
|
| Nutrition Surveys | 1 | 2013 | 327 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 955 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2020 | 5122 | 0.020 |
Why?
|
| Research Design | 2 | 2008 | 723 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2010 | 84 | 0.020 |
Why?
|
| Life Style | 1 | 2013 | 444 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2013 | 393 | 0.020 |
Why?
|
| Motor Activity | 1 | 2013 | 508 | 0.020 |
Why?
|
| Arginine | 1 | 2011 | 344 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2006 | 2298 | 0.020 |
Why?
|
| Autophagy | 1 | 2012 | 424 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 2018 | 1132 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2009 | 83 | 0.020 |
Why?
|
| Injections | 1 | 2008 | 115 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2009 | 137 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2010 | 723 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 1998 | 4052 | 0.020 |
Why?
|
| Swine | 1 | 2011 | 1190 | 0.020 |
Why?
|
| Exercise Tolerance | 1 | 2008 | 89 | 0.020 |
Why?
|
| Dactinomycin | 1 | 2007 | 48 | 0.020 |
Why?
|
| Receptors, Ghrelin | 1 | 2007 | 29 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 1600 | 0.020 |
Why?
|
| Growth Hormone | 1 | 2007 | 127 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2007 | 199 | 0.020 |
Why?
|
| Neuropeptides | 1 | 2007 | 111 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2012 | 807 | 0.020 |
Why?
|
| ROC Curve | 1 | 2009 | 623 | 0.020 |
Why?
|
| Phenylalanine | 1 | 2006 | 126 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2007 | 227 | 0.010 |
Why?
|
| Prevalence | 1 | 2013 | 2695 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 1303 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 1745 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 2006 | 227 | 0.010 |
Why?
|
| Hong Kong | 1 | 2005 | 16 | 0.010 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2005 | 18 | 0.010 |
Why?
|
| Syndrome | 1 | 2007 | 1170 | 0.010 |
Why?
|
| Life Tables | 1 | 2004 | 27 | 0.010 |
Why?
|
| Acute Disease | 1 | 2007 | 1153 | 0.010 |
Why?
|
| Angina, Unstable | 1 | 2004 | 49 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2006 | 341 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 3093 | 0.010 |
Why?
|
| Metallothionein | 1 | 2004 | 16 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 2004 | 148 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 2146 | 0.010 |
Why?
|
| Desoxycorticosterone | 1 | 2003 | 12 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2005 | 322 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2003 | 91 | 0.010 |
Why?
|
| Superoxides | 1 | 2003 | 129 | 0.010 |
Why?
|
| NADPH Oxidases | 1 | 2003 | 108 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2005 | 427 | 0.010 |
Why?
|
| Plicamycin | 1 | 2002 | 4 | 0.010 |
Why?
|
| Base Sequence | 1 | 2006 | 2783 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2003 | 187 | 0.010 |
Why?
|
| Vasodilation | 1 | 2003 | 174 | 0.010 |
Why?
|
| Butadienes | 1 | 2002 | 22 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2003 | 321 | 0.010 |
Why?
|
| Chromatography, Gel | 2 | 1972 | 78 | 0.010 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2002 | 45 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 2991 | 0.010 |
Why?
|
| Molecular Weight | 2 | 1972 | 297 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2002 | 366 | 0.010 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2002 | 74 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2003 | 314 | 0.010 |
Why?
|
| Heart Failure | 2 | 2005 | 2307 | 0.010 |
Why?
|
| Nitriles | 1 | 2002 | 165 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2005 | 600 | 0.010 |
Why?
|
| Transferrin | 1 | 2001 | 45 | 0.010 |
Why?
|
| Linear Models | 1 | 2003 | 695 | 0.010 |
Why?
|
| Reference Values | 1 | 2002 | 692 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2003 | 471 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2003 | 518 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2002 | 567 | 0.010 |
Why?
|
| Binding Sites | 1 | 2002 | 1202 | 0.010 |
Why?
|
| Adolescent | 2 | 2009 | 20987 | 0.010 |
Why?
|
| Health Priorities | 1 | 1999 | 42 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1999 | 135 | 0.010 |
Why?
|
| Mass Screening | 1 | 2005 | 825 | 0.010 |
Why?
|
| Congresses as Topic | 1 | 1999 | 187 | 0.010 |
Why?
|
| Protein Binding | 1 | 2002 | 1712 | 0.010 |
Why?
|
| Research | 1 | 1999 | 269 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2004 | 999 | 0.010 |
Why?
|
| DNA | 1 | 2002 | 1442 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 2353 | 0.010 |
Why?
|
| Hospitalization | 1 | 2004 | 1942 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1999 | 1253 | 0.010 |
Why?
|
| Cytosine Nucleotides | 1 | 1972 | 1 | 0.010 |
Why?
|
| Ammonium Sulfate | 1 | 1972 | 4 | 0.010 |
Why?
|
| Uracil Nucleotides | 1 | 1972 | 9 | 0.010 |
Why?
|
| Chemical Precipitation | 1 | 1972 | 11 | 0.010 |
Why?
|
| Polynucleotides | 1 | 1972 | 7 | 0.010 |
Why?
|
| Guanine Nucleotides | 1 | 1972 | 13 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1972 | 54 | 0.010 |
Why?
|
| Chymotrypsinogen | 1 | 1971 | 1 | 0.010 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1972 | 50 | 0.010 |
Why?
|
| Adenine Nucleotides | 1 | 1972 | 37 | 0.010 |
Why?
|
| Yeasts | 1 | 1972 | 42 | 0.010 |
Why?
|
| Dextrans | 1 | 1971 | 45 | 0.010 |
Why?
|
| Gels | 1 | 1971 | 70 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1972 | 428 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1972 | 579 | 0.010 |
Why?
|
| RNA | 1 | 1972 | 531 | 0.000 |
Why?
|
| Bacteria | 1 | 1971 | 532 | 0.000 |
Why?
|